MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Just Happened with Praxis's Vormatrigine Program

1 week ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Just Happened with BD and Waters

3 months ago

What Just Happened with Generate Biomedicines' IPO

3 months ago

What Just Happened with Trump's Tariffs, and Why Does it Matter

3 months ago

What Just Happened with uniQure's Earnings and FDA Update

3 months ago

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Neurogene completed dosing in the Embolden registrational trial of NGN-401 for Rett syndrome, a key milestone toward potential regulatory submission.

NGNE

News•1 week ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Pharmaceutical companies are testing new methods to bypass the blood-brain barrier for Alzheimer's treatments. Results from these delivery initiatives are expected to emerge throughout this year, pote...

Stock News•1 week ago

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision Medicines shares may face volatility after the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary endpoint for treating focal onset seizures. The company is now reasses...

PRAX

Stock News•2 weeks ago

Biohaven: Despite Today's Gains, I Remain Skeptical

Biohaven Ltd. provided an R&D update covering its epilepsy, autoimmune, Parkinson's, and obesity programs. The company expects pivotal topline data for its epilepsy asset later this year, serving as a...

BHVN